scholarly article | Q13442814 |
P50 | author | Douglas Jabs | Q5301649 |
Jennifer Thorne | Q61877550 | ||
John H Kempen | Q63819726 | ||
Robert B. Nussenblatt | Q83234942 | ||
Grace A Levy-Clarke | Q83235015 | ||
Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study | Q83235469 | ||
P2093 | author name string | C Stephen Foster | |
Ebenezer Daniel | |||
Eric B Suhler | |||
James T Rosenbaum | |||
Marc H Levin | |||
Maxwell Pistilli | |||
Sapna S Gangaputra | |||
P2860 | cites work | Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop | Q24727581 |
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study | Q33321092 | ||
Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis | Q33322621 | ||
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity | Q33360668 | ||
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study | Q33478325 | ||
Hypopyon in patients with uveitis | Q33518200 | ||
Cyclosporine for ocular inflammatory diseases | Q33520584 | ||
Cigarette smoking as a risk factor for uveitis | Q33695558 | ||
Risk of relapse in primary acute anterior uveitis | Q33934732 | ||
Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases | Q34224273 | ||
Risk of hypotony in noninfectious uveitis | Q34337589 | ||
Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography | Q35570770 | ||
Adverse effects of smoking on patients with ocular inflammation | Q35582576 | ||
Degree, duration, and causes of visual loss in uveitis. | Q35592376 | ||
The impact of macular edema on visual function in intermediate, posterior, and panuveitis. | Q36814725 | ||
Methotrexate for ocular inflammatory diseases | Q37204512 | ||
Causes and frequency of blindness in patients with intraocular inflammatory disease | Q37319691 | ||
Azathioprine for ocular inflammatory diseases | Q37366679 | ||
Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. | Q46520542 | ||
Risk factors for the development of macular edema in noninfectious uveitis. | Q51060569 | ||
Long-term visual outcome and complications associated with pars planitis | Q58397008 | ||
Effect of lymphocytic infiltration on the blood-retinal barrier in experimental autoimmune uveoretinitis | Q68158018 | ||
International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease | Q69741243 | ||
Pathology of human cystoid macular edema | Q70574403 | ||
Role of the vitreous in the prognosis of peripheral uveitis | Q72542156 | ||
Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema | Q77156632 | ||
Risk factors for cystoid macular oedema in patients with uveitis | Q79196584 | ||
Impact of macular edema on visual acuity in uveitis | Q80023608 | ||
Course of macular edema in uveitis under medical treatment | Q80454666 | ||
Long-term follow-up of inflammatory cystoid macular edema | Q83823317 | ||
P433 | issue | 2 | |
P921 | main subject | uveitis | Q280027 |
visual impairment | Q737460 | ||
P304 | page(s) | 588-95.e1 | |
P577 | publication date | 2013-12-12 | |
P1433 | published in | Ophthalmology | Q7098109 |
P1476 | title | Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema | |
P478 | volume | 121 |
Q90614897 | Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis |
Q94333937 | Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis |
Q35681664 | Clinical trials in noninfectious uveitis |
Q92691394 | Cochrane corner: why we still don't know whether anti-TNF biologic therapies impact uveitic macular oedema |
Q41592704 | Correlation between Visual Acuity, Inner Segment/Outer Segment Junction, and Cone Outer Segment Tips Line Integrity in Uveitic Macular Edema |
Q37349073 | Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis |
Q36310489 | Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial |
Q90397147 | Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges |
Q36218114 | Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results |
Q61810687 | Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis |
Q53107185 | Quantitative analysis of vitreous inflammation using optical coherence tomography in patients receiving sub-Tenon's triamcinolone acetonide for uveitic cystoid macular oedema. |
Q40661330 | Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis. |
Q38953088 | Structure-function Relationships in Uveitic Cystoid Macular Edema: Using En Face Optical Coherence Tomography to Predict Vision |
Q28068067 | The effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocol |
Q54641208 | [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014]. |
Search more.